News

Men, women, gay, straight – it really just kinds of expands the opportunity for prevention’ Source: Twice-a-year shot to prevent HIV could stop transmission — if people can get it – Zimbabwe News Now ...
The FDA has approved a new, twice-yearly PrEP injection from pharmaceutical giant Gilead. The drug is lenacapavir. The ...
Gilead Sciences, Inc. GILD obtained FDA approval for its twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, for the ...
The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show ...
The U.S. Food and Drug Administration this week approved Gilead Sciences’ twice-a-year shot, lenacapvir, to prevent HIV, Gilead announced on Wednesday, June 18. It is the first and only long-acting ...
The breakthrough double injection won’t be cheap in the US, although scientists argue it could (and should) be.
FDA approves Yeztugo HIV prevention injection showing 96% efficacy in clinical trials, but $14,000 cost creates significant access barriers for patients.
In two recent studies, this new shot reportedly nearly eliminated new infections in people at substantial risk of HIV.
“This is a historic day in the decades-long fight against HIV,” Gilead CEO Daniel O’Day said in the company’s announcement.
A drug currently used to treat certain HIV infections has also, on Wednesday, received approval from the US Food and Drug ...
The injectable HIV prevention treatment Yetzugo, made by Gilead Sciences, has received FDA approval, offering a twice-yearly alternative to daily medications.